We are close to June 30th and the expected termination of the trial recruiting. Reach finally the expected 168 patients count is a first brick in our wall of perpetuity.
Now after the last patient in, we will have the still the time laps for terminating his trial, so another minimum 12 weeks or three months minimum.
Afterwards we have final clinical data retrieval, assembling and exposure to the world audience (4Q2018 and/or before Christmas). At least I hope so.
Which timing do you believe the company will follow to present these data from now to the final FDA submission?
What is the expected time frame to get a final answer from the FDA?
Any idea what should be the best course of actions to be taken by the company after having finalized the Phase II results?
What about the unidentified waiting time lapse for an hopeful Phase II successful FDA approval?
Will again be blocked as was with EMA in a strenuous and stressful waiting game?
Do you remember all the time loss (and money lost due to the high operating expenses) that the company had during the previous unsuccessful EMA presentation?
Previous CEO was just waiting and praying from the sunrise to the sunset for the decision. The office was just crossing hands and did everything possible to get time.
So what is the company plan during the idle time frame that separate us to the possible partners decision, the Phase III preparation and the new timeless EMA submission?
Are we going to get time dealing with the new product pipeline?
Let's try to build some expectation for this company as the trial is finalizing.
Thank you all for the exercise and the scenario building that is required at this stage.
This time we have to be winners. At least this is what current management would expect and promised to us.
After the TIS debacle this was Dr. Cherrel Hirst promises to all shareholder. During the AGM she said: "We have got this wrong, but we will make it!".
So let's now deliver. We are ready after so much labor to get some refreshment. Isn't it?
FTT Price at posting:
4.4¢ Sentiment: Buy Disclosure: Held
